FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046483229> ?p ?o ?g. }

• W3046483229 endingPage "150" @default.
• W3046483229 startingPage "142" @default.
• W3046483229 abstract "Abstract Objective To evaluate the expression of inducible nitric oxide synthases (iNOS/NOS2) in human glioma and its correlation with patients’ prognoses. Methods IiNOS/NOS2 expression in tumor and corresponding normal tissues of glioma patients was analyzed using the TCGA database and the online analysis tool GEPIA. The mutation statuses of iNOS/NOS2 genes were also explored in the TCGA database using cBioPortal. Co-expressed genes relevant to iNOS/NOS2 were screened by LinkedOmics. Gene ontology (GO) and KEGG pathway enrichment for iNOS/NOS2 and co-expressed genes was performed using LinkedOmics. Overall survival (OS) and disease-free survival (DFS) outcomes between iNOS/NOS2 mRNA high and low expression groups were compared using a log-rank test. Twenty-two glioma patients who underwent operation were included in the present work. A real-time PCR assay was used to detect iNOS/NOS2 mRNA expression in tumor tissue and normal brain tissue. Results There was no statistical difference in iNOS/NOS2 mRNA expression levelss between tumor and normal tissues of glioma. A real-time PCR assay indicated that iNOS/NOS2 mRNA expression in tumor tissue and normal brain tissues were not statistical difference (p>0.05). A mutation rate of 0.8% for the iNOS/NOS2 gene was found using 1044 glioma patients from two datasets. The mutation types include deep deletion (0.4%), truncating (0.2%) and missense (0.2%). The top positive and negative co-expressed gene with iNOS/NOS2 were COL25A1 (r pearson =0.4734, p<0.05) and ALCAM (r pearson =0.4734, p<0.05), respectively. For KEGG pathway analysis, iNOS/NOS2 was mainly enriched in calcium signaling pathway, Wnt signaling pathway, GnRH signaling pathway, HIF-1 signaling pathway and pathways in cancer. The overall survival (HR=2.0, p<0.05) and disease-free survival (HR=1.6, p<0.05) values were significantly different between iNOS/NOS2 high and low expression groups. Conclusion OS and DFS were significantly decreased in high iNOS/NOS2 mRNA expression groups. iNOS/NOS2 can be used as a poor prognostic biomarker for glioma." @default.
• W3046483229 created "2020-08-07" @default.
• W3046483229 creator A5016953985 @default.
• W3046483229 creator A5047230992 @default.
• W3046483229 creator A5059888725 @default.
• W3046483229 creator A5067028141 @default.
• W3046483229 date "2020-01-01" @default.
• W3046483229 modified "2023-09-25" @default.
• W3046483229 title "Bioinformatics analysis of the expression of inducible nitric oxide synthases (iNOS/NOS2) in human glioma and its correlation with patients’ prognoses" @default.
• W3046483229 cites W1548694790 @default.
• W3046483229 cites W187300631 @default.
• W3046483229 cites W1967140644 @default.
• W3046483229 cites W1975011653 @default.
• W3046483229 cites W1981934473 @default.
• W3046483229 cites W1988801216 @default.
• W3046483229 cites W1992635430 @default.
• W3046483229 cites W2007087158 @default.
• W3046483229 cites W2009029293 @default.
• W3046483229 cites W2041187831 @default.
• W3046483229 cites W2042024019 @default.
• W3046483229 cites W2062960775 @default.
• W3046483229 cites W2072379045 @default.
• W3046483229 cites W2154094237 @default.
• W3046483229 cites W222902041 @default.
• W3046483229 cites W2270676474 @default.
• W3046483229 cites W2415587673 @default.
• W3046483229 cites W2535144714 @default.
• W3046483229 cites W2565233113 @default.
• W3046483229 cites W2577535432 @default.
• W3046483229 cites W2579492303 @default.
• W3046483229 cites W2607129810 @default.
• W3046483229 cites W2663091579 @default.
• W3046483229 cites W2757881705 @default.
• W3046483229 cites W2767377392 @default.
• W3046483229 cites W2781525129 @default.
• W3046483229 cites W2949112913 @default.
• W3046483229 doi "https://doi.org/10.1515/pteridines-2020-0019" @default.
• W3046483229 hasPublicationYear "2020" @default.
• W3046483229 type Work @default.
• W3046483229 sameAs 3046483229 @default.
• W3046483229 citedByCount "3" @default.
• W3046483229 countsByYear W30464832292021 @default.
• W3046483229 countsByYear W30464832292022 @default.
• W3046483229 countsByYear W30464832292023 @default.
• W3046483229 crossrefType "journal-article" @default.
• W3046483229 hasAuthorship W3046483229A5016953985 @default.
• W3046483229 hasAuthorship W3046483229A5047230992 @default.
• W3046483229 hasAuthorship W3046483229A5059888725 @default.
• W3046483229 hasAuthorship W3046483229A5067028141 @default.
• W3046483229 hasBestOaLocation W30464832291 @default.
• W3046483229 hasConcept C104317684 @default.
• W3046483229 hasConcept C134018914 @default.
• W3046483229 hasConcept C142724271 @default.
• W3046483229 hasConcept C150194340 @default.
• W3046483229 hasConcept C152724338 @default.
• W3046483229 hasConcept C153911025 @default.
• W3046483229 hasConcept C2777622882 @default.
• W3046483229 hasConcept C2778227246 @default.
• W3046483229 hasConcept C2987395477 @default.
• W3046483229 hasConcept C501734568 @default.
• W3046483229 hasConcept C502942594 @default.
• W3046483229 hasConcept C519581460 @default.
• W3046483229 hasConcept C54355233 @default.
• W3046483229 hasConcept C71924100 @default.
• W3046483229 hasConcept C75563809 @default.
• W3046483229 hasConcept C86803240 @default.
• W3046483229 hasConceptScore W3046483229C104317684 @default.
• W3046483229 hasConceptScore W3046483229C134018914 @default.
• W3046483229 hasConceptScore W3046483229C142724271 @default.
• W3046483229 hasConceptScore W3046483229C150194340 @default.
• W3046483229 hasConceptScore W3046483229C152724338 @default.
• W3046483229 hasConceptScore W3046483229C153911025 @default.
• W3046483229 hasConceptScore W3046483229C2777622882 @default.
• W3046483229 hasConceptScore W3046483229C2778227246 @default.
• W3046483229 hasConceptScore W3046483229C2987395477 @default.
• W3046483229 hasConceptScore W3046483229C501734568 @default.
• W3046483229 hasConceptScore W3046483229C502942594 @default.
• W3046483229 hasConceptScore W3046483229C519581460 @default.
• W3046483229 hasConceptScore W3046483229C54355233 @default.
• W3046483229 hasConceptScore W3046483229C71924100 @default.
• W3046483229 hasConceptScore W3046483229C75563809 @default.
• W3046483229 hasConceptScore W3046483229C86803240 @default.
• W3046483229 hasIssue "1" @default.
• W3046483229 hasLocation W30464832291 @default.
• W3046483229 hasLocation W30464832292 @default.
• W3046483229 hasOpenAccess W3046483229 @default.
• W3046483229 hasPrimaryLocation W30464832291 @default.
• W3046483229 hasRelatedWork W2002027447 @default.
• W3046483229 hasRelatedWork W2009966535 @default.
• W3046483229 hasRelatedWork W2021523535 @default.
• W3046483229 hasRelatedWork W2126157643 @default.
• W3046483229 hasRelatedWork W247954563 @default.
• W3046483229 hasRelatedWork W2580080859 @default.
• W3046483229 hasRelatedWork W2748644580 @default.
• W3046483229 hasRelatedWork W2754087939 @default.
• W3046483229 hasRelatedWork W4205963003 @default.
• W3046483229 hasRelatedWork W1983205518 @default.
• W3046483229 hasVolume "31" @default.

• next